NCT02989844已完成2 期
Relapse Prophylaxis With IL-15 Super Agonist N-803 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Following Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Incidence of Relapse
研究概览
简要总结
This is a single-arm, multi-center Phase II trial using IL-15 super-agonist complex (N-803 formerly known as Alt-803) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant using a reduced intensity conditioning is planned or has been performed and patient is prior to day 60 post-transplant.
- •Able to begin study treatment between day +42 and day +60 after the transplant and meets the following transplant related requirements:
- •Sustained neutrophil (ANC > 1000/mcL) and platelet (> 30,000/mcL) engraftment
- •>50% donor myeloid and lymphoid chimerism blood or bone marrow on most recent bone marrow (BM) evaluation
- •No evidence of recurrent disease on most recent bone marrow evaluation (day 21 or 28 post-transplant is acceptable)
- •No morphologic evidence of relapse (< 5% bone marrow blasts) on most recent BM evaluation (Day 21 or 28 post-transplant is acceptable)
- •Being followed in the outpatient setting (not an inpatient)
- •No plan of giving other anti-cancer treatment directed at diseases under study (i.e. maintenance therapy [e.g. sorafenib for FLT3m+ AML or hypomethylating therapy], additional therapy for MRD)
- •If acute GVHD is present it must be clinically improving on topical steroids and/or on low dose systemic steroids (≤ 0.3 mg/kg/day prednisone) and with clinical stability for at least 1 week prior to determination of eligibility. GVHD prophylaxis will be continued per individual institutional standard practice
- •One of the following donor graft sources used for the transplant:
- •Group 1: sibling donor
- •Group 2: haploidentical donor [with post-transplant cyclophosphamide]
- •Group 3: unrelated donor
- •Group 4: unrelated umbilical cord blood
- •Karnofsky performance status ≥ 70%
- •Adequate organ function within 14 days of study enrollment defined as:
- •Renal: serum creatinine: ≤ 2.0 mg/dL
- •Hepatic: SGOT ≤ 3 x upper limit of institutional normal (ULN)
- •Sexually active females of child-bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy.
- •Voluntary written consent prior to the performance of any research related procedures
排除标准
- •Prior N-803 (previously known as ALT-803)
- •Pregnant or breastfeeding - N-803 is an investigational agent. Women of child bearing potential must have a negative pregnancy test at screening.
- •Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)
- •Marked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval > 500 milliseconds)
- •Active uncontrolled bacterial, fungal, or viral infections - all prior infections must have resolved following optimal therapy and must be afebrile for at least 24 hours at time of enrollment.
- •Active autoimmune disease requiring immunosuppressive therapy (GVHD prophylaxis is permitted per institutional practice)
- •History of severe asthma and currently on chronic medications (mild asthma requiring inhaled steroids only is eligible)
- •Received any investigational agent within the 14 days before the start of study treatment (1st dose of N-803)
研究组 & 干预措施
N-803
Experimental
干预措施: N-803 (Drug)
结局指标
主要结局
Incidence of Relapse
时间窗: 24 months
Efficacy of N-803 as measured by the cumulative incidence of relapse between the 1st dose of N-803 and 2 years after a reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplant (alloHCT)
次要结局
- Incidence of Adverse Events(12 months)
- Incidence of Acute Graft-versus-host Disease(Day 180)
- Chronic GVHD(1 year)
- Overall Survival(1 year post transplant)
- Minimal Residual Disease (MRD)(1 year)
- Relapse(2 Years)
- Non-Relapse Mortality(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia AHemophilia ANCT01233258Bayer80
终止
2 期
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for ChemotherapyAcute Myeloid LeukemiaNCT04150029Novartis Pharmaceuticals90
招募中
2 期
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialMetastatic Breast CancerNCT06342037The Netherlands Cancer Institute60
尚未招募
2 期
A Dose Ranging Study to Examine TDS-Testosterone 5%HypogonadotropismNCT01894308Transdermal Delivery Solutions Corp48
已完成
2 期
A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) TherapyHepatitis B, ChronicNCT05276297GlaxoSmithKline174